MEDS DataMeds AI, Inc.
$0.90▲ +0.91%
Healthcare
Other
After hours
$0.90▼ -0.12%
Sep 11, 7:50 PM ET
Volume 87.9K
Avg Volume (10D) 922.0K
Key Metrics & Fundamentals
Market Cap
$2.76M
P/E Ratio
–
Div Yield
–%
52W Range
0.82 - 80.45
% vs 50 MA
-59.09%
% vs 200 MA
-90.89%
RSI-14
27.8
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.80
Free Cash Flow
-$3.14M
Gross Rev
$1.78M
Gross Profit
$182,204
EBITDA
-$6.48M
COGS
$1.60M
Operating Exp
$7.53M
Operating Income
-$7.35M
EBIT
-$7.35M
Pretax Income
-$18.36M
Net Income
-$18.36M
EPS (Diluted)
-7.13
Price & Volume History
Loading chart…
Recent News
Datameds, AI., and Tollo Health Partner with the NFL Alumni Association for Health Lives Here National Campaign Rollout
ACCESS Newswire · Sep 8, 2026 10:00 AM
DataMeds AI and Tollo Health Announce Fall 2026 Cold & Flu #Back2School50% Marketing Campaign for Viral Infections Medical Food Galectovid(TM)
ACCESS Newswire · Aug 27, 2026 12:55 PM
DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update
ACCESS Newswire · Aug 17, 2026 1:00 PM
DataMEDS AI Announces Its Board of Directors Approved September 9, 2026 as the Payment Date of the Previously Announced Distribution of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of August 7, 2026
ACCESS Newswire · Aug 14, 2026 9:25 PM
DataMeds AI Provides Update on Corexa Health's Pharmacy Division
ACCESS Newswire · Aug 12, 2026 11:40 AM
DataMeds AI's Corexa Pharmacy Launches Tollo Health's Tollovid(R) and Galactovid(TM)
ACCESS Newswire · Jul 31, 2026 12:30 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See MEDS's money flow as a full page
Social Sentiment
Avg -0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.